[4] Ray-Coquard I,Morice P,Lorusso D,et al.Non-epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv1-iv18. [5] Shah JS,Guerra R,Bodurka DC,et al...
Bristol Myers Squibb announced the presentation of scientific research across several solid tumors showcasing the breadth of the Company’s oncology development program at the European Society for Medical Oncology Congress 2022 from September 9-13 in Par
[4] Ray-Coquard I,Morice P,Lorusso D,et al.Non-epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv1-iv18. [5] Shah JS,Guerra R,Bodurka DC,et al.Factors influencing fertility-sparing treatment for gynecologic ...
[4] Ray-Coquard I,Morice P,Lorusso D,et al.Non-epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv1-iv18. [5] Shah JS,Guerra R,Bodurka DC,et al.Factors influencing fertility-sparing treatment for gynecologic ...
相关心脏毒性的预防及治疗干预。目前不少发达国家,已经建立了肿瘤心脏病专科门诊、病房和对应的多学科治疗团队 ( , )。而在 国内,相关学科发展才刚刚开始。可以预见的是,随着乳腺癌检测和治 疗手段的不断进步,会有越来越多的乳腺癌患者获得长期的生存,这意味着 ...
[4] Ray-Coquard I,Morice P,Lorusso D,et al.Non-epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv1-iv18. [5] Shah JS,Guerra R,Bodurka DC,et al.Factors influencing fertility-sparing treatment for gynecologic...
[4] Ray-Coquard I,Morice P,Lorusso D,et al.Non-epithelial ovarian cancer:ESMO clinical practice guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2018,29(Suppl 4):iv1-iv18. [5] Shah JS,Guerra R,Bodurka DC,et al.Factors influencing fertility-sparing treatment for gynecologic...